Clone:
REA820
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC
Alternative names:
PROM1, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4

Extended validation for CD133/2 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA820
293C3++
AC133-
AC141++
clone 7-
EMK08-
REA753-
REA816++
REAL233-
S16015F-
S16016B-
S16016E++
TMP4-
W6B3C1-
Cells were incubated with an excess of purified unconjugated CD133/2 (REA820) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD133/2. Human peripheral blood mononuclear cells (PBMCs) were stained with CD133/2 antibodies and with a suitable counterstaining. As a control, CD133/2 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD45+ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD133/2 (REA820). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD133/2 (REA820). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD133/2 (REA820). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD133/2 Antibody, anti-human, REAfinity™

Overview

Clone REA820 recognizes the epitope 2 of the human CD133 antigen (CD133/2). CD133 is a marker that is frequently found on multipotent progenitor cells, including immature hematopoietic stem and progenitor cells, in human fetal liver, bone marrow, cord blood, and peripheral blood. CD133 has also been found to be expressed on circulating endothelial progenitor cells, tissue-specific stem cells, cancer stem cells from tumor tissues, as well as ES and iPS cell–derived cells.
Additional information: Clone REA820 displays negligible binding to Fc receptors.

Alternative names

PROM1, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4

Detailed product information

Technical specifications

CloneREA820
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman
AntigenCD133/2
Alternative names of antigenPROM1, CORD12, MCDR2, MSTP061, PROML1, RP41, STGD4
Molecular mass of antigen [kDa]117
Distribution of antigenendothelial cells, epithelial cells, red blood cells, hematopoietic stem and progenitor cells, ES and iPS cells, brain, heart, kidney, liver, lung, pancreas, placenta
Entrez Gene ID8842
RRIDAB_2654910, AB_2654911, AB_2654912, AB_2654913, AB_2654914, AB_2654915, AB_2654916, AB_2654917, AB_2654918, AB_2654919, AB_2654909

Resources for CD133/2 Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD133/2 Antibody, anti-human, REAfinity™

Publications

  1. Lai, J. et al. (2014)
    Id1 and NF-κB promote the generation of CD133
    +
    and BMI-1
    +
    keratinocytes and the growth of xenograft tumors in mice.
    Int. J. Oncol. 44(5): 1481-1489

Related products for
CD133/2 Antibody, anti-human, REAfinity™

2 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?